MD logo

Pediatrix Medical Group, Inc. Stock Price

NYSE:MD Community·US$1.9b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 10 Fair Values set on narratives written by author

MD Share Price Performance

US$24.30
10.48 (75.83%)
US$21.33
Fair Value
US$24.30
10.48 (75.83%)
13.9% overvalued intrinsic discount
US$21.33
Fair Value
Price US$24.30
AnalystConsensusTarget US$21.33
AnalystHighTarget US$27.00
AnalystLowTarget US$19.00

MD Community Narratives

·
Fair Value US$21.33 13.9% overvalued intrinsic discount

MD: Share Repurchase Plan And Margin Gains Will Support Future Performance

0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
·
Fair Value US$27 10.0% undervalued intrinsic discount

US Pediatric Growth And Telehealth Expansion Will Elevate NICU Care

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
·
Fair Value US$19 27.9% overvalued intrinsic discount

Rising Reimbursement Risks And Labor Shortages Will Erode Margins

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
US$27
10.0% undervalued intrinsic discount
Revenue
3.82% p.a.
Profit Margin
8.61%
Future PE
12.91x
Price in 2029
US$32.91
US$21.33
13.9% overvalued intrinsic discount
Revenue
2.64% p.a.
Profit Margin
8.28%
Future PE
10.97x
Price in 2029
US$26

Trending Discussion

Updated Narratives

MD logo

MD: Hospital Fee Pressures And Clinical Uncertainty Will Weigh On Future Returns

Fair Value: US$19 27.9% overvalued intrinsic discount
0 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
MD logo

MD: Future Returns Will Rely On Tennessee Expansion That Supports Buybacks

Fair Value: US$27 10.0% undervalued intrinsic discount
1 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
MD logo

MD: Ongoing Buybacks And Firmer Margins Will Support A Balanced Future Outlook

Fair Value: US$21.33 13.9% overvalued intrinsic discount
3 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Undervalued with excellent balance sheet.

2 Risks
3 Rewards

Pediatrix Medical Group, Inc. Key Details

US$1.9b

Revenue

US$1.4b

Cost of Revenue

US$504.0m

Gross Profit

US$329.8m

Other Expenses

US$174.2m

Earnings

Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
n/a
2.17
26.09%
9.02%
67.2%
View Full Analysis

About MD

Founded
1979
Employees
4280
CEO
Mark Ordan
WebsiteView website
www.pediatrix.com

Pediatrix Medical Group, Inc., together with its subsidiaries, provides newborn, maternal-fetal, and other pediatric subspecialty care services in the United States. The company offers clinical care to babies born prematurely or with complications within specific units at hospitals, primarily NICUs, through its network of affiliated neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; and inpatient and office-based clinical care to expectant mothers and unborn babies through its affiliated maternal-fetal medicine subspecialists, obstetricians and other clinicians, maternal-fetal medicine nurse practitioners, certified nurse midwives, sonographers, and genetic counselors. It also provides other pediatric subspecialty care, including pediatric intensivists, pediatric hospitalists, and pediatric surgeons; support services in other areas of hospitals comprising pediatric emergency room, labor and delivery area, and nursery and pediatric departments; a newborn hearing screening program. The company was formerly known as MEDNAX, Inc. and changed its name to Pediatrix Medical Group, Inc. in July 2022. Pediatrix Medical Group, Inc. was founded in 1979 and is based in Sunrise, Florida.

Recent MD News & Updates

Narrative Update Jun 10

MD: Hospital Fee Pressures And Clinical Uncertainty Will Weigh On Future Returns

Analysts have kept the Pediatrix Medical Group price target steady at $19.00, citing only marginal updates to assumptions for discount rate, revenue growth, profit margin and future P/E that do not materially change their overall outlook. What's in the News Pediatrix Medical Group highlighted new research on probiotic use and necrotizing enterocolitis in preterm infants, finding that necrotizing enterocolitis rates rose in hospitals that sharply reduced probiotic use after 2023 FDA warnings and market withdrawals.
Narrative Update May 27

MD: Higher Discount Rate And Lower P/E Expectations Will Pressure Outlook

Analysts have kept their price target for Pediatrix Medical Group steady at $19.00, citing updated assumptions that include a slightly higher discount rate, modestly adjusted revenue growth and profit margin expectations, and a somewhat lower future P/E multiple. What's in the News Pediatrix Medical Group expanded in Middle Tennessee through a partnership with Tennessee Maternal-Fetal Medicine, rebranding the practice as Maternal-Fetal Medicine Specialists of Tennessee under the Pediatrix banner, with five locations in the Greater Nashville area and a team of four board-certified physicians and six advanced practice providers (Key Developments).

Recent updates

No updates